Associated Genetic Biomarkers

Overview

NCI Definition: A carcinoma that infiltrates the breast parenchyma. The vast majority are adenocarcinomas arising from the terminal ductal lobular unit (TDLU). Often, the invasive adenocarcinoma co-exists with ductal or lobular carcinoma in situ. It is the most common carcinoma affecting women. [1]

Invasive breast carcinomas most frequently harbor alterations in TP53, PIK3CA, ERBB2, GATA3, and CCND1 [2].

Most Commonly Altered Genes in Invasive Breast Carcinoma

PIK3CA Mutation, TP53 Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, and PIK3CA Codon 1047 Missense are the most common alterations in invasive breast carcinoma [2].

Top Alterations in Invasive Breast Carcinoma

Significant Genes in Invasive Breast Carcinoma

ATM +

ATR +

BARD1 +

BRCA1 +

BRCA2 +

BRIP1 +

CHEK2 +

ERBB2 +

FANCA +

FANCC +

FANCD2 +

FANCE +

FANCF +

FANCM +

FGFR1 +

FGFR2 +

FGFR3 +

FGFR4 +

MRE11A +

NBN +

PALB2 +

PIK3CA +

RAD50 +

RAD51C +

RAD51D +

Disease Details

Synonyms
Invasive Breast Cancer, infiltrating breast cancer, Invasive Carcinoma of Breast, Invasive Carcinoma of the Breast, Infiltrating Carcinoma of the Breast, invasive breast cancer, Invasive breast carcinoma, Infiltrating Breast Carcinoma, Invasive Mammary Carcinoma, Infiltrating Carcinoma of Breast
Parent(s)
Breast Carcinoma
Children
Squamous Cell Breast Carcinoma, Breast Neuroendocrine Carcinoma, Metaplastic Breast Carcinoma, Breast Invasive Ductal Carcinoma, Breast Invasive Lobular Carcinoma, Signet Ring Cell Breast Carcinoma, Invasive Breast Carcinoma, NOS, Adenoid Cystic Breast Carcinoma, Invasive Breast Cribriform Carcinoma, Mucoepidermoid Breast Carcinoma, Adenosquamous Breast Carcinoma, Inflammatory Breast Carcinoma, and Invasive Papillary Breast Carcinoma
OncoTree Name
Invasive Breast Carcinoma
OncoTree Code
BRCA

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.